|本期目录/Table of Contents|

[1]赖香茂,刘晓萍,曾健文,等.坦索罗辛联合托特罗定治疗慢性前列腺炎/慢性盆腔疼痛综合征[J].分子影像学杂志,2017,(02):179.
点击复制

坦索罗辛联合托特罗定治疗慢性前列腺炎/慢性盆腔疼痛综合征(PDF)
分享到:

《分子影像学杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2017年02期
页码:
179
栏目:
出版日期:
2017-04-20

文章信息/Info

Title:
Evaluation of combination therapy with tamsulosin and tolterodine for the treatment of chronic prostatitis/chronic pelvic pain syndrome
作者:
赖香茂刘晓萍曾健文刘建家曾少华
Author(s):
-
关键词:
坦索罗辛托特罗定慢性前列腺炎/慢性盆腔疼痛综合征临床观察
Keywords:
tamsulosin tolterodine chronic prostatitis/chronic pelvic pain syndrome evaluation
分类号:
-
DOI:
-
文献标志码:
-
摘要:
目的 探讨坦索罗辛联合托特罗定治疗慢性前列腺炎/慢性盆腔疼痛综合征的临床疗效。方法 将我院符合研究标准的 64例确诊为慢性前列腺炎/慢性盆腔疼痛综合征的患者随机分为对照组和观察组。对照组给予口服坦索罗辛(0.2 mg,1次/d) 联合抗菌药物治疗,观察组在此基础上联合使用托特罗定(4 mg,1次/d)治疗。两组患者于药物治疗前及连续用药12周后进 行慢性前列腺炎症状评分、视觉模拟评分,比较最大尿流率、平均尿流率及前列腺液中的白细胞数目,评估治疗效果,并在治 疗期间评估患者的用药依从性情况。结果 经治疗后,观察组患者慢性前列腺炎症状总评分(16.34±4.31)、视觉模拟评分 (4.22±1.70)、白细胞数目(7.16±3.35)、排尿症状评分(2.78±1.56)、QOL评分(5.44±2.23)以及用药依从性评分(0.84±0.85)均有 下降。最大尿流率(19.47±4.69)、平均尿流率(11.91±3.85)显著升高,且各项指标均优于对照组(分别为24.16±4.95、6.34±1.62、 14.78±4.64、5.78±2.09、8.41±2.67、1.22±0.67),差异具有统计学意义(P<0.05)。结论 坦索罗辛联合托特罗定治疗慢性前列腺 炎/慢性盆腔疼痛综合征能获得更好的疗效,值得临床重视。
Abstract:
Objeetive To evaluate the effect of combination therapy of toherodine and tamsulosin in improving symptoms in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Methods A total of 64 patients with CP/CPPS in our hospital were randomized into control group and observation group, with 32 cases in each group. The control group was treated with tamsulosin (2 mg, qd), while the observation group was treated with tamsulosin (2 mg, qd) combined with tolterodine (4 mg, qd). Chronic prostatitis symptom index (CPSI), Visual analogue scale (VAS), maximum flow rate (MFR), average flow rate (AFR), white blood cell (WBC) of ESP were compared before treatment and after 12 weeks. The patients’ compliance in two groups’ patients was investigated as well. Results After treatment, The observation group have decreased in NIH-CPSI (16.34±4.31), VAS (4.22±1.70), WBC (7.16±3.35), urinary symptom score (2.78±1.56), QOL (5.44±2.23) and Morisky (0.84±0.85). MFR (19.47±4.69)、AFR (11.91±3.85) were significantly increased, and the indexes were better than control group (24.16±4.95、6.34±1.62、14.78±4.64、5.78±2.09、8.41±2.67、1.22±0.67).The difference was statistically significant (P<0.05). Conclusion Combination therapy of toherodine and tamsulosin is better than tamsulosin hydrochloride alone in treatment of CP/CPPS.

参考文献/References:

-

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 1900-01-01